425379-12-0

Basic information

• Product Name: 2-(3-BROMOIMIDAZO[1,2-B][1,2,4]TRIAZIN-7-YL)PROPAN-2-OL
• Synonyms: 2-(3-BROMOIMIDAZO[1,2-B][1,2,4]TRIAZIN-7-YL)PROPAN-2-OL
• CAS NO: 425379-12-0
• Molecular Formula: C₈H₉BrN₄O
• Molecular Weight: 257.08726
• Mol File: 425379-12-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3-BROMOIMIDAZO[1,2-B][1,2,4]TRIAZIN-7-YL)PROPAN-2-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-BROMOIMIDAZO[1,2-B][1,2,4]TRIAZIN-7-YL)PROPAN-2-OL(425379-12-0)
• EPA Substance Registry System: 2-(3-BROMOIMIDAZO[1,2-B][1,2,4]TRIAZIN-7-YL)PROPAN-2-OL(425379-12-0)

Safety Data

• Hazardous Substances Data: 425379-12-0(Hazardous Substances Data)

Usage

Classification

Organic compound
Belongs to the class of carbon-containing compounds.

Subclass

Imidazopyrimidines
A group of organic compounds characterized by a fused ring structure derived from imidazole and pyrimidine.

Antiviral activity

Inhibitory against human cytomegalovirus (HCMV) and herpes simplex virus (HSV)
Exhibits antiviral properties by interfering with the replication and functioning of the mentioned viruses.

Potential use

Treatment of viral infections
Has been studied for its possible application in treating viral infections, particularly in immunocompromised patients.

Chemical structure

Bromoimidazo triazine ring and a propan-2-ol group
The presence of these functional groups in the compound's structure contributes to its antiviral properties.

Therapeutic potential

Promising as a therapeutic agent against certain viral diseases
Due to its antiviral activity, 2-(3-Bromoimidazo[1,2-b][1,2,4]triazin-7-yl)propan-2-ol shows potential for treating specific viral infections.

Upstream product

• 425379-11-9 2-(imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol 

Relevant articles and documents

Discovery of imidazo[1,2-b][1,2,4]triazines as GABAA α2/3 subtype selective agonists for the treatment of anxiety

The identification of a series of imidazo[1,2-b][1,2,4]triazines with high affinity and functional selectivity for the GABAA α3-containing receptor subtype is described, leading to the identification of a clinical candidate, 11. Compound 11 shows good bioavailability and half-life in preclinical species, and it is a nonsedating anxiolytic in both rat and squirrel monkey behavioral models.

IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS

A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a -NH- linkage, and substituted on the phenyl ring by one or two further substituents as defined herein, being selective ligands for GABAA receptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS

A class of imidazo[1,2b][1,2,4]triazine derivatives, substituted at the 7-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having good affinity for the α2 a

Imidazo-triazine derivatives as ligands for GABA receptors

A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by a (cyano)(fluoro)phenyl moiety, being selective ligands for GABAA receptors, in particular having good affinity for the α2 and/